<DOC>
	<DOCNO>NCT02501850</DOCNO>
	<brief_summary>Lipoprotein ( ) [ Lp ( ) ] independent cardiovascular risk ( CVR ) general population patient type 2 diabetes mellitus ( DM-2 ) . Until effective treatment know decrease level Lp ( ) level thus achieve reduction CVR . Among new antidiabetic drug GLP-1Receptor agonist ( GLP-1R ) . In addition lower blood glucose , drug beneficial effect . In laboratory demonstrate native GLP-1 various GLP-1R agonsits reduce synthesis Lp ( ) hepatocytes . The objective study test human result observe vitro . We analyze whether treatment GLP-1R agonist ( Liraglutide , Exenatide Lixisenatida ) reduce serum level Lp ( ) patient DM-2 .</brief_summary>
	<brief_title>The Effect GLP-1 Receptor Agonists Blood Levels Lipoprotein ( )</brief_title>
	<detailed_description>Background : Lipoprotein ( ) [ Lp ( ) ] independent cardiovascular risk ( CVR ) general population patient type 2 diabetes mellitus ( DM-2 ) . Until effective treatment know decrease level Lp ( ) level thus achieve reduction CVR . Among new antidiabetic drug GLP-1Receptor agonist ( GLP-1R ) . In addition lower blood glucose , drug beneficial effect . In laboratory demonstrate native GLP-1 various GLP-1R agonsits reduce synthesis Lp ( ) hepatocytes . Hypothesis : Treatment GLP-1R agonist low level Lp ( ) patient DM-2 . Objective : The objective study confirm human result observe vitro . We analyze whether treatment GLP-1R agonist ( Liraglutide , Exenatide Lixisenatida ) reduce serum level Lp ( ) patient DM-2 . Methods : evaluate 40 patient DM-2 treated Endocrinology Department Vall d'Hebron University Hospital . The patient distribute two group accord treatment prescribed endocrinologist visit routine monitoring : group A ( 20 patient prescribred treatment GLP-1R agonist ) group B ( 20 patient prescribed treatment ) . According current guideline treat DM-2 , GLP-1R agonist situate second line treatment metformin , treatment individualize accord characteristic patient . ( Inzucchi et al . Management hyperglycemia type 2 diabetes : patient-centered approach : position statement American Diabetes Association ( ADA ) European Association Study Diabetes ( EASD ) Diabetes Care 2012 ; 35 ( 6 ) : .. 1364-1379 ) . Following recommendation , GLP-1R agonist usually select obesity / important avoid hypoglycaemia . The decision prescribe GLP-1R agonist make endocrinologist independently patientÂ´s participation study . Blood level Lp ( ) evaluate baseline 2 month ( +/- 15 day ) . Diabetic patient treated insulin , enzyme inhibitor DPP-4 ( IDDP-4 ) already treat receptor agonists GLP-1 , present kidney liver failure , HbA1c &gt; 10 % , LDL-cholesterol &gt; 180 mg / dl / triglycerides &gt; 350 mg / dl exclude . Relevance : The result identify potential treatment lowering level Lp ( ) patient DM-2 thus reduce cardiovascular risk associate lipoprotein .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Type 2 diabetes age 5065 year write informed consent active GLP1R agonist , insulin DPPIV treatment . Liver failure ( 3lsn AST and/or ALT ) Kidney failure ( FG &lt; 30ml/min/1,73m2 ) , HbA1c &gt; 10 % LDLcholesterol &gt; 180 mg/dl Triglycerides &gt; 350 mg/dl</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Lipoprotein ( )</keyword>
</DOC>